Пренеса

Quick links to important sections

Пренеса

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Пренеса

1. Identity, Classification, and Origin of Prenesa

Prenesa is a prescription-only medicinal product, manufactured by Krka, containing the active ingredient Perindopril. It is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, a class of medications used to modulate vascular tension and fluid balance. Perindopril is a synthetic compound that functions as a prodrug. This means the molecule remains inactive until it is metabolized within the body into its active form, Perindoprilat, which is necessary for its systemic effect as an antihypertensive agent.


2. Composition, Form, and General Cardiovascular Purpose

The medication is a single-ingredient product produced as a film-coated tablet for oral administration. Its composition includes the Perindopril salt—such as the tert-butylamine salt—combined with solid pharmaceutical excipients designed to ensure stable delivery. The primary purpose of this ACE inhibitor is to support the management of the cardiovascular system by facilitating vasodilation (the widening of blood vessels) and reducing peripheral vascular resistance. This action is intended to reduce the workload on the heart by managing the resistance within the circulatory system, typically for adult patients requiring cardiovascular support.

What side effects are possible with Пренеса?

Possible Side Effects and Safety Information

The safety profile of Пренеса (Perindopril) is officially documented by regulatory authorities, classifying potential adverse reactions by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into several categories based on clinical and post-marketing data:

  • Common (may affect up to 1 in 10 people): Reactions frequently noted include a dry, persistent cough, dizziness, headache, and mild gastrointestinal issues such as nausea or diarrhoea. Hypotension (low blood pressure) is also common, especially at the start of treatment.
  • Uncommon: These reactions may include angioedema (swelling of the face or throat), sleep disturbances, pruritus (itching), or mood alterations.
  • Very Rare: Extremely rare reactions, reported in less than 1 in 10,000 people, may include hepatic failure (severe liver damage) or agranulocytosis (severe reduction in white blood cells).

Serious Adverse Reactions and Safety Considerations

The most serious adverse reaction documented is Angioedema, which involves swelling of the larynx or glottis and carries a risk of airway obstruction. Other serious reactions include acute renal failure and, very rarely, severe blood disorders.

Population-Specific Safety: The medicine is contraindicated for use during the second and third trimesters of pregnancy due to the high documented risk of fetal harm. Specific monitoring is advised for older adults and patients with pre-existing renal impairment due to altered drug clearance and an increased risk of hyperkalaemia (high potassium levels). Safety documents also note that hypotension is most likely to occur after the very first dose or subsequent dose increases.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented clinical manifestations and regulator-mandated emergency actions for an overdose of Пренеса (Perindopril), as stated in government regulatory sources.

Overdose scope Details (Strictly Label-Derived)
Documented overdose presentations: The primary presentation is marked hypotension (severe low blood pressure), often accompanied by bradycardia (slowed heart rate) or dizziness. Potential manifestations include electrolyte disturbances and acute renal failure.
Physiological systems affected: The Cardiovascular System and Renal System are primarily affected, with risks including circulatory shock.
Population-specific overdose notes: Severity, particularly the risk of acute renal failure, is considered heightened in patients with pre-existing renal impairment.
Emergency-response statements: Seek immediate medical attention or contact emergency services immediately upon suspicion of overdose or the appearance of severe symptoms like syncope (fainting) or circulatory shock.

Overdose classifications (high-level)

Classification Details (Strictly Regulatory)
Severity classification: Classified as a severe or life-threatening scenario when complicated by circulatory shock or acute renal failure.
Regulatory basis: Information is based on official prescribing guidelines from government drug authorities.
Overdose-context constraints: No specific antidote is known for the ACE inhibitor effect, mandating treatment that is strictly symptomatic and supportive.

Official overdose statements

  • Overdose presents primarily with marked hypotension and may lead to circulatory shock or acute renal failure.
  • Immediate medical attention is required upon suspicion of overdose or onset of severe symptoms.
  • Treatment is symptomatic and supportive, aiming to restore blood pressure through intravenous volume expansion.
  • Hemodialysis is listed as an option for the removal of the active metabolite, Perindoprilat.
  • Close and continuous monitoring of blood pressure and renal function is necessary during the observation period.

Connection to the overall overdose profile: Regulatory documents define the Perindopril overdose profile by its primary risk of inducing severe hemodynamic imbalance, evidenced by marked hypotension and potential circulatory shock. This framework mandates that individuals must seek immediate medical attention when overdose is suspected. Management is explicitly defined as symptomatic and supportive, with procedural steps like volume expansion listed due to the stated absence of a specific antidote.

Therapeutic Uses of Пренеса

The therapeutic application of Prenesa is relevant in contexts involving key chronic cardiovascular conditions.

Management of Chronic High Blood Pressure and Vascular Strain

This medication plays a role in the long-term management of high blood pressure (Hypertension). Its primary benefit provides continuous support to assist in managing blood pressure levels, generally contributing to a reduction in overall cardiovascular system burden and functional stability.

Secondary Prevention and Symptom Support

Prenesa is considered relevant for secondary prevention in individuals with established stable coronary artery disease or following a previous heart attack or stroke. A key benefit in this context is its role in supporting the reduction of risk for future major complications, including myocardial infarction and stroke. Furthermore, in cases of mild to moderate chronic heart failure, it is used for managing physical symptom clusters like persistent fatigue and shortness of breath during exertion.

“The goal of this therapy is generally to help patients maintain functional stability and assist in reducing long-term cardiovascular risk.”


  • Quick Fact: Relief for Systemic Strain Prenesa is commonly used to help address symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Пренеса?

The eligibility for using Пренеса (Perindopril) is strictly determined by regulatory authorities based on specific contraindications and patient status. The medicine is primarily authorized for adult patients (18 and over).

Contraindicated and Restricted Populations

Certain conditions and populations prohibit or restrict use, as defined in the official prescribing information:

Status or Condition Eligibility Rule
History of Angioedema Contraindicated (absolute prohibition).
Pregnancy (2nd & 3rd Trimesters) Contraindicated (absolute prohibition).
Children & Adolescents (Under 18) Not Recommended (safety/efficacy not established).
Concomitant Use with Sacubitril/Valsartan Contraindicated (36-hour washout period required).
Severe Renal or Hepatic Impairment Conditional Use (requires close monitoring).
Breastfeeding Not Recommended.

Use is contraindicated if a patient has a known hypersensitivity to Perindopril or any other ACE inhibitor. Treatment for older adults may require careful initial monitoring based on the official guidelines.

What should I know about interactions with other medicines?

The active substance in Пренеса, perindopril, is an Angiotensin-Converting Enzyme (ACE) inhibitor whose interactions primarily stem from its effect on the Renin-Angiotensin-Aldosterone System (RAAS).

Contraindicated and High-Risk Combinations

Interacting Product Category Restriction and Mechanism
Neprilysin Inhibitors (NI), e.g., Sacubitril/Valsartan Contraindicated. Must not be used within 36 hours of each other due to a significantly increased risk of angioedema (serious swelling).
Direct Renin Inhibitors (DRIs), e.g., Aliskiren Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min) due to heightened risk of hypotension, hyperkalemia, and renal dysfunction.

Combinations Requiring Caution

  • Potassium-Elevating Agents: Concomitant use with potassium-sparing diuretics (e.g., Spironolactone, Triamterene), potassium supplements, or potassium-containing salt substitutes is generally not recommended as it significantly increases the risk of hyperkalemia (high blood potassium).
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs, including selective COX-2 inhibitors, may reduce the blood pressure-lowering effect of perindopril and increase the risk of worsening renal function, especially in the elderly or dehydrated patients.
  • Lithium: ACE inhibitors can reduce the renal clearance of lithium, leading to increased serum lithium concentrations and risk of lithium toxicity. If combined, frequent monitoring of lithium levels is required.
  • mTOR Inhibitors (e.g., Sirolimus, Everolimus): Concurrent use may increase the risk of angioedema.

Mechanism of Action

Пренеса is a human immunoglobulin G2 (IgG2) monoclonal antibody that specifically targets and binds to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). This binding prevents RANKL from engaging its cognate receptor, RANK, which is expressed on the surface of pre-osteoclasts and mature osteoclasts.

By blocking this ligand-receptor interaction, Пренеса functionally inhibits the activation of the RANK/RANKL signaling pathway. This pathway is essential for osteoclastogenesis (the formation), activation (function), and survival of osteoclasts. The resulting suppression of this signaling cascade leads to a significant decrease in the number and activity of these bone-resorbing cells.

This cellular consequence ultimately modulates the physiological balance of bone turnover by favoring bone formation over breakdown, resulting in a system-level decrease in osteoclast-mediated bone resorption within the skeletal system.

Dosage and Administration Information

Пренеса is administered orally as a film-coated tablet, available in standard strengths such as 2 mg, 4 mg, and 8 mg. The core usage principle involves a low starting dose followed by gradual adjustment, known as titration, to reach the appropriate long-term maintenance dose.

The administration of the tablet occurs once daily, preferably in the morning and before a meal (e.g., before breakfast). This specific timing is directed by the need to optimize the body’s conversion of the prodrug to its active therapeutic form, Perindoprilat. If a dose is missed, standard practice is to simply skip the missed dose and resume the schedule at the next designated time; doubling the dose is prohibited.

Dosing Regimens and Adjustments

For the management of hypertension, therapy typically begins with 4 mg once daily, with the dose potentially increasing to a usual maintenance range of 4 mg to 8 mg, up to a maximum of 16 mg per day. When used for stable coronary artery disease, the initial dose is generally 4 mg daily for two weeks, followed by an increase to the 8 mg maintenance dose.

Specific dosage modifications are required for certain populations. For patients with renal impairment, the starting dose is lowered to 2 mg/day and should not exceed 8 mg/day if the creatinine clearance is 30 mL/min or greater. In older adults (e.g., over 70), titration is slowed, beginning with 2 mg daily for the first week when treating stable coronary artery disease. This continuous regimen forms the basis of the standard use protocol.

Recent Clinical Evidence

Recent Clinical Evidence

Mechanism of Action Studies

Research has explored whether the drug acts by affecting a specific pathway. This mechanism has been studied for its potential role in influencing changes in pain levels and changes in symptom relief in patients. Clinical research has focused on the drug’s ability to interact with cellular receptors involved in inflammation. Research indicates that this interaction was investigated.


Clinical Efficacy Research

Phase II Trials (Short-Term Outcomes)

Early-stage trials evaluated whether the use of the drug was associated with changes in short-term pain scores. In a 12-week study, researchers observed data suggesting a potential reduction in self-reported pain intensity among participants compared to the placebo group. Studies have evaluated whether changes in joint mobility were examined, investigating a potential reduction in swelling. Research has focused on the drug’s role in managing symptoms of moderate-to-severe joint discomfort.

Phase III Trials (Long-Term Data)

Studies compared this therapy to standard care and evaluated its potential role in studies exploring pain-related outcomes. Findings from a six-month, multicenter trial examined the potential for the drug to affect joint function. Research examined whether participants may see results within the first week of treatment.

A systematic review explored whether the drug was associated with reduced reliance on rescue medication over a 12-month period. Evidence remains limited regarding long-term structural changes to joints.


Safety and Tolerability Profile

Clinical trials investigated the drug’s tolerability, focusing on adverse event reporting. The most commonly reported events included mild gastrointestinal upset and headache. Research has examined its use in people with kidney issues. Phase I studies also evaluated the drug's initial tolerability.

Frequently Asked Questions (FAQ)

Common questions about Пренеса (FAQ)

Q: What's the difference between Пренеса and medicines ending in '-pril'?

The active substance in Пренеса is Perindopril, which belongs to a class of medicines called ACE (Angiotensin-Converting Enzyme) inhibitors. Medicines with names ending in '-pril' are typically members of this same class, which works by blocking an enzyme in the body that causes blood vessels to narrow. This action is the main mechanism for controlling high blood pressure and other cardiovascular conditions.

Q: Does taking Пренеса mean I have to limit any specific foods or drinks?

Regulatory documents advise caution regarding certain food components and alcohol. Potassium supplements and salt substitutes that contain potassium are generally not recommended due to a risk of high blood potassium levels. Official information also advises caution with alcohol consumption, particularly when treatment begins, as there may be an increased risk of dizziness or low blood pressure.

Q: Do I need regular blood tests while I'm on Пренеса?

Regulatory documents indicate that regular monitoring by a healthcare provider may be necessary during treatment. Blood tests may be required to check for potential unwanted effects, such as changes in kidney function or elevated potassium levels in the blood (hyperkalemia).

Q: Does Пренеса interact with commonly prescribed antidepressants?

Regulatory documents list interactions with the medication Lithium, which is sometimes used to treat mood disorders, and caution is required due to the risk of toxicity if combined. Official information recommends disclosing all current medications to a healthcare provider for a proper interaction assessment.

Q: Does Пренеса help with anything besides hypertension?

According to official product information, Perindopril is also indicated for the treatment of stable coronary artery disease to reduce the risk of cardiovascular events. It may also be used in certain patients with heart failure to manage symptoms and ease the heart's workload.

Q: Is it normal to feel a little dizzy when first starting Пренеса?

Yes, regulatory documents list dizziness as a common side effect of Perindopril. This feeling is often due to the initial drop in blood pressure and is most likely to occur after taking the very first dose or shortly after any subsequent dose increase.

Q: Are there any major side effects I should watch out for with Пренеса?

The most serious documented adverse reaction is Angioedema (swelling of the face, throat, or tongue), which is considered a medical emergency. Other serious considerations include very low blood pressure (hypotension) and sudden acute renal failure (kidney problems).

Q: Can I take Пренеса if I'm already taking supplements like potassium or magnesium?

Official interaction guidance states that concomitant use with potassium supplements is generally not recommended because it significantly increases the risk of high blood potassium (hyperkalemia). Magnesium is not specifically listed as a contraindicated supplement, but it is important for a healthcare provider to be aware of all supplements being taken.

Q: Does taking Пренеса cause weight gain or loss?

Changes in body weight are not listed among the commonly or uncommonly reported side effects in the official regulatory documents. Changes in appetite are not listed among the common or uncommon side effects in the regulatory documents.

Q: Why is Пренеса sometimes combined with a diuretic?

ACE inhibitors like Perindopril are often combined with diuretics (water pills) to enhance the overall blood pressure-lowering effect. This is a common strategy to address different mechanisms of blood pressure control when a single medication is not sufficiently effective.

Q: How long can someone safely stay on Пренеса?

Perindopril is intended for the long-term management of chronic cardiovascular conditions such as hypertension and stable coronary artery disease. Long-term efficacy and safety have been supported by clinical trials and regulatory approval for continuous use.

Q: Can Пренеса affect blood sugar levels?

Official safety information indicates that Perindopril may potentially lower blood sugar levels in patients who have diabetes. This may require more frequent blood glucose monitoring as determined by a healthcare professional, particularly during the initial weeks of treatment.

Q: Are there generic versions of Пренеса available?

Yes, the active ingredient in Пренеса, Perindopril, is widely available as a generic medicine. Regulatory agencies authorize generic versions, which contain the same active ingredient and are expected to work comparably to the branded product.

Q: Is it better to take Пренеса in the morning or at night?

Official administration instructions state that the tablet should be taken once daily, preferably in the morning and before a meal. This timing is generally advised to optimize the way the body converts the medicine into its active, therapeutic form.

Q: Does Пренеса affect energy levels or cause fatigue?

Regulatory documents list lack of strength (asthenia) and general fatigue among the reported side effects. Additionally, common side effects like dizziness and uncommon ones like sleep disturbances are documented. Patients who experience changes in their sleep patterns or fatigue are advised to discuss this with their healthcare provider.

Q: Does Пренеса help protect the heart?

Yes, official indications state that by treating high blood pressure and reducing vascular resistance, this medicine helps to ease the heart's workload. Furthermore, it is specifically indicated to lower the risk of future cardiovascular events in patients with a history of stable coronary artery disease.

Q: Is there a list of all possible side effects for Пренеса?

Yes, comprehensive lists of all known and reported side effects, categorized by frequency (common, uncommon, rare, etc.), are documented in the full regulatory prescribing information. This detailed information is contained within the official product information and labeling for the medicine.

Q: How is Пренеса eliminated from the body?

The active substance of this medicine is primarily broken down into its active form, Perindoprilat, which is then mainly eliminated from the body by the kidneys. This renal clearance is relevant to why kidney function is often monitored during the course of treatment.

Q: Why might a doctor increase or decrease the dosage of Пренеса over time?

Dosage is often adjusted to find the optimal level that achieves and maintains effective blood pressure control or the target maintenance dose for stable coronary artery disease. Adjustments are also required for specific patient populations, such as those with reduced kidney function or older adults, where lower starting doses may be appropriate.

Q: Are there any common interactions between Пренеса and over-the-counter cold medicines?

Official drug interaction information advises caution when combining ACE inhibitors with sympathomimetic agents, which are often found in decongestant-type cold medicines. This combination may potentially reduce the effectiveness of the blood pressure treatment or cause unwanted cardiovascular effects.

Q: Does Пренеса affect sleep?

Sleep disturbances are listed as an uncommon adverse reaction in the official safety documents for Perindopril. Patients who experience changes in their sleep patterns are advised to discuss this with their healthcare provider.

Q: Do patients generally tolerate Пренеса well?

Clinical trial data indicate that while many patients tolerate the medicine well, the most common reasons reported for patients needing to stop treatment were side effects such as a persistent cough, drug intolerance, and overly low blood pressure (hypotension).

Q: Is it necessary to take Пренеса with food?

Official instructions specify that the tablet should be taken before a meal, such as before breakfast, rather than with food. This helps to ensure the optimal absorption and conversion of the medicine into its active form.

How should Пренеса be stored and disposed of?

The official regulatory documents specify strict conditions for the storage and disposal of Пренеса (Perindopril) tablets.

Required Storage Conditions

Storage Factor Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep the container tightly closed and store in the original container to protect the tablets from moisture.
Child Safety Keep out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Пренеса must be disposed of in compliance with local guidelines for pharmaceutical waste. Regulatory guidance instructs against discarding the medicine in household garbage or flushing it down the toilet or drain, as this prevents environmental contamination. Patients should utilize designated drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Пренеса found in:

A-Z Index: